Pharming awarded 'Best Biotechnology Company' by the World Technology Network
(Thomson Reuters ONE) -
Leiden, The Netherlands, December 2, 2010. Pharming Group NV ("Pharming") (NYSE
Euronext: PHARM) today announced that last night it received the Award for Best
Biotechnology Company for 2010 by the World Technology Network (WTN) at the
World Technology Summit (November 30-December 1, 2010) in New York City.
Pharming has been awarded for its innovative work on production of life
enhancing drugs derived from its transgenic platform, an achievement viewed by
the voting committee as one of the greatest likely long-term significant
achievements within the science and technology arena.
The World Technology Awards are presented annually by the WTN at a dinner of its
World Technology Summit to individuals and corporations achieving significant,
lasting progress in categories pertaining to science, technology, finance, IT,
design, and many more. The first World Technology Summit and Awards took place
on November 12, 1999 in London. Last night's Awards dinner was held at the Time
Life Building in Manhattan and the awards are presented in association with
Time, NASDAQ, Fortune, AAAS, Science, NYAS, and The Technology Review.
Sijmen de Vries, Pharming's CEO, said, "This has been a highly significant year
for Pharming with the European approval of our lead product Ruconest for
treatment of acute attacks of Hereditary Angioedema. This highly innovative
product is produced through Pharming's proprietary transgenic technology and
will be launched this year. Ruconest has been in clinical development with the
needs of patients at the forefront of our drive to get this to market. We are
delighted to accept this award on behalf of the entire Pharming team as
recognition for their commitment and hard work."
Previous winners have included Alnylam, Advanced Cell Technology, Amyris
Biotechnologies, Genencor International, Genentech, International Rice Genome
Sequencing Project.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet
medical needs. Ruconest(TM) (Rhucin® in non-European territories) is a
recombinant human C1 inhibitor approved for the treatment of angioedema attacks
in patients with HAE in all 27 EU countries plus Norway, Iceland and
Liechtenstein. The product is also under development for follow-on indications,
i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF)
following kidney transplantation. The advanced technologies of the Company
include innovative platforms for the production of protein therapeutics,
technology and processes for the purification and formulation of these products.
Additional information is available on the Pharming website,www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54
[HUG#1467947]
Press release (PDF):
http://hugin.info/132866/R/1467947/405594.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 02.12.2010 - 10:20 Uhr
Sprache: Deutsch
News-ID 49333
Anzahl Zeichen: 4239
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 175 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming awarded 'Best Biotechnology Company' by the World Technology Network"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
